Sulfation Attenuates Mitigating Effects of 25‐Hydroxycholesterol on Postmenopausal Bone Loss
The FASEB Journal · 2026
DOI: 10.1096/fj.202600557r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von He Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Northwest University, Xi'an, China. Hauptthemen laut MEDLINE: Hydroxycholesterols, Osteoporosis, Postmenopausal. Die Arbeit nennt 41 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of China.
Abstract (Originalsprache)
Postmenopausal osteoporosis is a prevalent skeletal disorder with an unmet need for safer therapeutic strategies. While certain oxysterols show osteoinductive potential, the role of 25‐hydroxycholesterol (25HC) in bone homeostasis remains unclear. Furthermore, 25HC can undergo sulfation, a largely underexplored chemical modification, to form 25HC3S. This study aimed to investigate the effects of 25HC and 25HC3S on bone loss and the underlying mechanisms. We found that treatment with 25HC, but not 25HC3S, ameliorated bone loss in an ovariectomized (OVX) mouse model of osteoporosis, as evidenced by increased bone mass and expression of type I collagen, alongside decreased osteoclast numbers. Transcriptomic analysis revealed that 25HC regulated genes related to cell cycle and Rho GTPase signaling in bone tissue and osteoblastic lineage cell cultures, while 25HC3S had attenuated effects. In vivo and in vitro experiments demonstrated that 25HC promoted pre‐osteoblast proliferation and enhanced osteocyte survival. Mechanistically, 25HC inhibited Rho GTPase signaling in pre‐osteoblasts but activated it in osteocytes, which was largely abolished by sulfation. Collectively, this study identifies 25HC as a protective regulator against postmenopausal bone loss and unveils sulfation as a critical switch that negates its benefit, supporting 25HC supplementation as promising therapeutic strategies for osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Northwest University, Xi'an, China.
- Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- School of Medicine, Northwest University, Xi'an, China.
ORCID-Profile: Liangjie Huang, Liu Yang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Ma, W., Niu, Y., Ji, X., Huang, L., Hu, J., Zhao, C., Yang, L., & Zheng, C. (2026). Sulfation Attenuates Mitigating Effects of 25‐Hydroxycholesterol on Postmenopausal Bone Loss. The FASEB Journal. https://doi.org/10.1096/fj.202600557r
Vancouver
Liu H, Ma W, Niu Y, Ji X, Huang L, Hu J, et al. Sulfation Attenuates Mitigating Effects of 25‐Hydroxycholesterol on Postmenopausal Bone Loss. The FASEB Journal. 2026. doi:10.1096/fj.202600557r
BibTeX
@article{Liu2026,
author = {Liu, He and Ma, Wenrui and Niu, Yichen and Ji, Xiaodan and Huang, Liangjie and Hu, Jingyan and Zhao, Chengxiang and Yang, Liu and Zheng, Chao},
title = {Sulfation Attenuates Mitigating Effects of 25‐Hydroxycholesterol on Postmenopausal Bone Loss},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202600557r}
}
EUVIMED